+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
S

Actively Recruiting

Researchers are evaluating an experimental drug called linvoseltamab REGN5458 in adults with relapsed or refractory multiple myeloma who have received one to four prior treatments and still have standard treatment options available. This study compares linvoseltamab to a combination of three cancer drugs elotuzumab, pomalidomide, and dexamethasone EPd. The goal is to assess the safety and effectiveness of linvoseltamab versus EPd, including how long participants benefit and the impact on their disease and symptoms. Participants are randomly assigned to receive either linvoseltamab given by intravenous infusion or the combination of elotuzumab IV infusion, pomalidomide oral capsules, and dexamethasone oral tablets or IV infusion. Half the participants receive linvoseltamab, and the other half receive the EPd combination. Treatments are monitored over time to evaluate responses and side effects. During the study, participants will have regular assessments including disease evaluations based on established criteria, pain assessments using the Brief Pain Inventory, and quality of life questionnaires. Researchers will track progression-free survival, overall survival, treatment responses, side effects, and other health measures for up to approximately five years. This includes monitoring blood levels of the study drug and immune responses. The total study duration extends to the primary completion date in 2033.

Age: 18Years +All GendersPhase 3
159 locations